Ignite Creation Date:
2024-05-05 @ 11:46 AM
Last Modification Date:
2024-10-26 @ 9:12 AM
Study NCT ID:
NCT00124449
Status:
COMPLETED
Last Update Posted:
2015-04-07
First Post:
2005-06-30
Brief Title:
Study of Abatacept Versus Placebo to Assess the Prevention of Rheumatoid Arthritis RA in Adult Patients
Sponsor:
Bristol-Myers Squibb
Organization:
Bristol-Myers Squibb
Study Overview
Official Title:
A Phase II Study of Abatacept Versus Placebo to Assess the Prevention of Rheumatoid Arthritis RA in Adult Patients With Undifferentiated Arthritis Who Are at High Risk for the Development of RA
Status:
COMPLETED
Status Verified Date:
2015-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to assess if Abatacept given for six months will prevent rheumatoid arthritis RA in patients who are at risk for the development of RA in comparison to placebo High risk patients are defined as those having a positive laboratory test for anti-cyclic citrullinated peptide anti-CCP2
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None